Neuland Laboratories Limited — Updates, 31-07-2025: Press Release

Neuland Labs' Q1FY26 saw total income at Rs 300.6 Cr and EBITDA at Rs 42.1 Cr, a significant year-on-year decline attributed to customer order flow. Despite the "below par" quarter, management maintains a positive outlook, anticipating healthy growth this financial year. They highlight ongoing investments as key drivers for short and long-term expansion, alongside a focus on cost optimization. The company expects substantial growth from commercial molecules and new business, continuing to invest in capabilities to enhance its CDMO differentiation. An earnings call is scheduled.